Events & Presentations

Date	Title
2026-01-12	Corporate Presentation

Date	Title
2025-10-27	Presentation - AACR NCI EORTC 2025 Discovery of AN4035 - CEACAM5 Targeting ADC armed with Proprietary Pan-RAS_ON Inhibitor Payload designed to broaden the therapeutic window
2025-10-27	Poster - AACR NCI EORTC 2025 - Discovery of AN4035 - CEACAM5 Targeting ADC armed with Proprietary Pan-RAS_ON Inhibitor Payload designed to broaden the therapeutic window
2025-04-29	PRESENTATION - AACR 2025 - AN9025, an Orally Bioavailable Pan-RAS(ON) Inhibitor With Potent, Broad-Spectrum Anti-Tumor Activity
2025-04-28	PRESENTATION - AACR 2025 - Coordinated Stimulation of APC and T Cell Functions by First-in-Class, Tri-Specific AN8025 for Next-Generation Cancer Immunotherapy
2024-11-11	PRESENTATION – SITC 2024 - A Phase I Study of AN4005, an Orally Available PD-L1 Inhibitor, in Patients with Advanced Tumors: Safety and Preliminary Efficacy
2024-09-14	PRESENTATION - ESMO 2024 - A Phase Ib Study of AN0025 in Combination With Definitive Chemoradiotherapy (dCRT) in Unresectable Locally Advanced or Locally Recurrent Esophageal Cancer (EC)
2023-10-22	PRESENTATION - ESMO 2023 - Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN
2023-05-31	PRESENTATION - ASCO 2023 - Combination of Immune and Genetic Biomarkers of Improved Efficacy to Buparlisib and Paclitaxel in Patients with SCCHN: BERIL-1 Sub-analysis
2019-09-29	PRESENTATION - ESMO 2019 - A Phase 1b Study of E7046 (AN0025) in Combination With Radiotherapy Chemoradiotherapy (RTCRT) in Preoperative Treatment of Rectal Cancer

Upcoming Events

Past Events